Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy

Science. 2015 Mar 20;347(6228):1362-7. doi: 10.1126/science.aaa1299.

Abstract

Neuronal excitation is regulated by energy metabolism, and drug-resistant epilepsy can be suppressed by special diets. Here, we report that seizures and epileptiform activity are reduced by inhibition of the metabolic pathway via lactate dehydrogenase (LDH), a component of the astrocyte-neuron lactate shuttle. Inhibition of the enzyme LDH hyperpolarized neurons, which was reversed by the downstream metabolite pyruvate. LDH inhibition also suppressed seizures in vivo in a mouse model of epilepsy. We further found that stiripentol, a clinically used antiepileptic drug, is an LDH inhibitor. By modifying its chemical structure, we identified a previously unknown LDH inhibitor, which potently suppressed seizures in vivo. We conclude that LDH inhibitors are a promising new group of antiepileptic drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticonvulsants / chemistry
  • Anticonvulsants / pharmacology*
  • Anticonvulsants / therapeutic use
  • Dioxolanes / chemistry
  • Dioxolanes / pharmacology*
  • Dioxolanes / therapeutic use
  • Disease Models, Animal
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • L-Lactate Dehydrogenase / antagonists & inhibitors*
  • Membrane Potentials / drug effects
  • Mice
  • Mice, Inbred ICR
  • Neurons / enzymology
  • Neurons / physiology
  • Patch-Clamp Techniques
  • Safrole / chemistry
  • Safrole / pharmacology*
  • Safrole / therapeutic use
  • Seizures / drug therapy*
  • Subthalamic Nucleus / enzymology

Substances

  • Anticonvulsants
  • Dioxolanes
  • Enzyme Inhibitors
  • L-Lactate Dehydrogenase
  • stiripentol
  • Safrole
  • isosafrole